logo

IRWD

Ironwood Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
4.54 / 10
Netural

Analyst sentiment is split between Buy (50%) and Neutral (50%) with only two active analysts, resulting in a low-confidence historical weighted rating of 1.39. Money flow is robust at 7.68/10, with positive Small and Medium inflows but negative overall and Extra-large trends, indicating that while retail and mid-sized investors are accumulating, larger institutions are exiting. This divergence underscores a cautious outlook, as sustained institutional support is lacking to propel the stock higher.

FundamentalSentiment(4.54)Technical
Fund Flow Rating
Analyst RatingBuy

Wall Street Opinions

Buy

Strong Buy

0%

Buy

50%

Hold

0%

Sell

0%

Strong Sell

0%

Date2026-01-05
InstitutionCitizens
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for IRWD?
  • IRWD holds a Bearish analyst rating, with 50% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.54/10 (Netural).